Efficacy and Safety of High Loading Dose of Colistin in Multidrug-Resistant Acinetobacter baumannii : A Prospective Cohort Study

Abstract

Objectives:

We aimed to assess the efficacy and safety of a high loading dose of colistin and no loading dose of colistin to treat multidrug-resistant (MDR) Acinetobacter baumannii infections.

Methods:

We conducted a prospective cohort study of patients with MDR A baumannii infections at a university-affiliated hospital from December 2014 to January 2016. In the high loading dose group, the patients received a high loading dose of 300 mg colistin base activity (CBA) followed by a maintenance dose of 150 mg CBA twice daily, and patients in the no loading dose group received only the maintenance dose. The primary outcome was clinical response. The secondary outcomes were 28-day mortality and microbiological response.

Results:

A total of 255 cases were identified. The high loading dose of colistin strategy provided no significant difference in good clinical response when compared to the no loading dose group (65.5% vs 70.4%; P = .442), without a significant difference in the development of renal dysfunction (52.3% vs 49.4%; P = .664). However, microbiological eradication was significantly higher among patients who received the high loading dose of colistin when compared to those who received the no loading dose (87.9% vs 70.4%; P = .0006).

Conclusions:

The high loading dose of colistin strategy was effective and safe for treating patients with MDR A baumannii.

Keywords

loading dose colistin

Get full access to this article

View all access options for this article.

References

Bergogne-Bérézin

Towner

. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev. 1996;9(2):148–165.

Keerasuntonpong

Samakeepanich

Tribuddharat

. Epidemiology of Acinetobacter baumannii infections in Siriraj Hospital. Siriraj Med J. 2006;58(8):951–954.

Chaiwarith

Mahatthanaphak

Boonchoo

, et al. Pandrug-resistant Acinetobacter baumannii at Maharaj Nakorn Chiang Mai Hospital. J Infect Dis Antimicrob Agents. 2005;22(1):1–8.

Kallel

Bahloul

Hergafi

, et al. Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int J Antimicrob Agents. 2006;28(4):366–369.

Plachouras

Karvanen

Friberg

, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother. 2009;53(8):3430–3436.

Ahern

Schnoor

. Colistin: potential for dosage error. Clin Infect Dis. 2012;55(9):1275–1276.

Mohamed

Karaiskos

Plachouras

, et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother. 2012;56(8):4241–4249.

Horan

Andrus

Dudeck

. CDC/NHSN surveillance definition of health care–associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–332.

Trifi

Abdellatif

Daly

, et al. Efficacy and toxicity of high-dose colistin in multidrug-resistant gram-negative bacilli infections: a comparative study of a matched series. Chemotherapy. 2016;61(4):190–196.

10.

Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: Twentieth Informational Supplement, M100-S20. Wayne, PA: Clinical and Laboratory Standards Institute; 2010.

11.

Dalfino

Puntillo

Mosca

, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis. 2012;54(12):1720–1726.

12.

Kellum

Bellomo

Ronco

. Definition and classification of acute kidney injury. Nephron Clin Pract. 2008;109(4):c182–c187.

13.

Garonzik

Thamlikitkul

, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55(7):3284–3294.

14.

Gibson

Bauer

Neuner

Bass

Lam

. Influence of colistin dose on global cure in patients with bacteremia due to carbapenem-resistant gram-negative bacilli. Antimicrob Agents Chemother. 2015;60(1):431–436.

15.

Falagas

Rafailidis

Ioannidou

, et al. Colistin therapy for microbiologically documented multidrug-resistant gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents. 2010;35(2):194–199.

16.

Karaiskos

Giamarellou

. Multidrug-resistant and extensively drug-resistant gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother. 2014;15(10):1351–1370.

17.

Pogue

Lee

Marchaim

, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011;53(9):879–884.

18.

Esterly

Griffith

Malczynski

Postelnick

Scheetz

. Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections. Antimicrob Agents Chemother. 2011;55(10):4844–4849.

19.

Lee

Kuo

Yang

, et al. Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection. Clin. Infect.Dis. 2012;55(2):209–215.

20.

Karaiskos

Friberg

Pontikis

, et al. Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate in critically ill patients. Antimicrob Agents Chemother. 2015;59(12):7240–7248.